Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
Thomas J. Borody1 MBBS, BSc(Med), MD, Ph.D., DSc, FRACP, FACP, FACG, AGAF
Robert L. Clancy2 AM, MB BS Ph.D. DSc FRACP FRCP(A)
1Centre for Digestive Diseases, Five Dock, NSW, Australia, 2046
2Faculty of Health and Medicine, University of Newcastle, NSW, Australia
The immediacy of “real-world” data in the pre-hospital treatment of Covid-19 using re-purposed drugs has been the keystone to the development of effective therapy in a pandemic situation. The sense of a “common-message database” for the therapeutic use of ivermectin (IVM) collated by clinicians over a time frame of little more than 12 months, involving patients and research workers across geographic and social lines, is extraordinary. From over 20 countries there are 63 controlled studies accepted for meta-analysis, that have included 47,500 subjects with 625 authors.
While this compelling database on the effectiveness of IVM would not be possible without “real-life” studies, at an individual level, these trials give additional value such as inf...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).